Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GUARDANT HEALTH, INC.

(GH)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/15/2021 09/16/2021 09/17/2021 09/20/2021 09/21/2021 Date
127(c) 126.98(c) 132.05(c) 129.16(c) 130.27 Last
519 981 487 552 1 445 884 624 150 438 837 Volume
-0.01% -0.02% +3.99% -2.19% +0.86% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 368 M - -
Net income 2021 -399 M - -
Net cash position 2021 101 M - -
P/E ratio 2021 -33,1x
Yield 2021 -
Sales 2022 502 M - -
Net income 2022 -333 M - -
Net Debt 2022 45,5 M - -
P/E ratio 2022 -39,7x
Yield 2022 -
Capitalization 13 196 M 13 196 M -
EV / Sales 2021 35,5x
EV / Sales 2022 26,4x
Nbr of Employees 864
Free-Float 95,6%
More Financials
Company
Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. It provides Guardant Health Oncology Platform. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for advanced stage cancer. Its liquid biopsy tests fuels its programs developing tests for recurrence and early detection, LUNAR-1 and... 
More about the company
Ratings of Guardant Health, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about GUARDANT HEALTH, INC.
09/15GUARDANT HEALTH : Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360« Liquid..
BU
09/14INSIDER SELL : Guardant Health
MT
09/07GUARDANT HEALTH : New Data at IASLC 2021 World Conference on Lung Cancer Demonstrates Adva..
AQ
09/02Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference
GL
08/23CONNECT BIOPHARMA : Names General Counsel & Chief Compliance Officer
MT
08/09GUARDANT HEALTH : Canaccord Genuity Adjusts Guardant Health's Price Target to $180 From $1..
MT
08/06GUARDANT HEALTH : to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit
BU
08/05GUARDANT HEALTH : Q2 Earnings Snapshot
AQ
08/05GUARDANT HEALTH : Management's Discussion and Analysis of Financial Condition and Results ..
AQ
08/05Guardant Health, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 20..
CI
08/05GUARDANT HEALTH : Announces New Leadership Structure Aligned with Strategic Growth Objecti..
BU
08/05GUARDANT HEALTH, INC. : Change in Directors or Principal Officers, Financial Statements an..
AQ
08/05GUARDANT HEALTH : Earnings Flash (GH) GUARDANT HEALTH Reports Q2 Revenue $92.1M, vs. Stree..
MT
08/05GUARDANT HEALTH : Earnings Flash (GH) GUARDANT HEALTH Reports Q2 Loss $-0.61, vs. Street E..
MT
08/05GUARDANT HEALTH, INC. : Results of Operations and Financial Condition (form 8-K)
AQ
More news
News in other languages on GUARDANT HEALTH, INC.
09/16GUARDANT HEALTH : stellt auf dem ESMO-Kongress 2021 Daten vor, die die Nützlichkeit der Gu..
09/15GUARDANT HEALTH : va présenter au congrès ESMO 2021 des données démontrant l'utilité de la..
03/03GUARDANT HEALTH : Guardant360« CDx Liquid Biopsy erhält die CE-Zertifizierung für umfassen..
03/02GUARDANT HEALTH : La biopsie liquide Guardant360« CDx obtient le marquage CE pour le profi..
01/19GUARDANT HEALTH : und das Vall d'Hebron Institute of Oncology geben Partnerschaft zur Einr..
More news
Analyst Recommendations on GUARDANT HEALTH, INC.
More recommendations
Chart GUARDANT HEALTH, INC.
Duration : Period :
Guardant Health, Inc. Technical Analysis Chart | GH | US40131M1099 | MarketScreener
Technical analysis trends GUARDANT HEALTH, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 15
Last Close Price 130,27 $
Average target price 161,31 $
Spread / Average Target 23,8%
EPS Revisions
Managers and Directors
Helmy Eltoukhy Chairman & Co-Chief Executive Officer
AmirAli H. Talasaz President, Co-Chief Executive Officer & Director
Michael Bell Chief Financial Officer
Kumud Kalia Chief Information Officer
Darya Chudova Senior Vice President-Technology
Sector and Competitors